Clinical Project Manager
Protara Therapeutics
Clinical Project Manager
Protara Therapeutics
Clinical-stage biopharma developing cancer therapies
Company Overview:
Protara Therapeutics is a clinical-stage biotechnology companycommitted to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
Protara was named one of the Best Places to Work by BioSpace, a leading industry news and job source. This honor demonstrates the company’s desirability in the recruitment marketplace, looking at various merits with an emphasis on culture, career growth and development opportunities, leadership and innovation. Attracting and retaining top talent is integral to building a successful company in biotech, and we are committed to ensuring Protara provides our employees with an exceptional experience throughout their careers, even as we continue to grow.
Job Overview:
The Clinical Project Manager, Temp to Perm, is responsible for supporting the Clinical Operations (CO) Team with all ongoing Protara programs as requested. Activities will include but are not limited to, acts as the secondary operational study contact for internal and external stakeholders, ensures Contract Research Organizations (CROs) are meeting their project deliverables within the agreed upon timelines, serves as the primary contact for Clinical Trial Manager(s) (CTMs) and Clinical Research Associates (CRAs), performs internal oversight of CTMs/CRAs performing CRO oversight monitoring visits, oversees global site selection and activation, reviews site budgets and contracts, supports document collection for RA/IRB submissions, implements recruitment strategies to meet enrollment objectives, oversees trial eTMFs, and tracks CRO’s Standard Operating Procedures (SOPs) for each trial.
Essential Duties and Responsibilities include the following (Other duties may be assigned):
Education:
Supervisory Responsibilities: No
Qualifications:
Other Skills and Abilities:
Compensation: Hourly Rate Requirements are between $68 - $78 based on experience and qualifications.
Why You’ll Love Working at Protara
Physical Demands:
The physical demands here are representative of those that must be met by an employee to successfully perform the essential functions of this job.
Work Environment:
The work environment characteristics described here are representative of those an employee encounters while performing the essential functions of this job.
To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed above are representative of the knowledge, skill, and/or ability required. Reasonable accommodation may be made to enable individuals with disabilities to perform the essential functions.
Protara is committed to being a diverse and inclusive workplace. Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, creed, religion, national or ethnic origin, citizenship status, age, sex or gender, gender identity or expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information or any other characteristic protected by applicable federal, state or local laws.
Clinical-stage biopharma developing cancer therapies
Protara Therapeutics operates as a clinical-stage biopharmaceutical company focused on therapies for cancer and rare diseases, funded by public markets with a cash runway into 2027. Lead asset TARA-002 is an immunopotentiator cell therapy derived from Streptococcus pyogenes, designed to stimulate innate and adaptive immunity in tumors, with NMIBC trials showing promising responses. A second asset, IV Choline Chloride, provides intravenous choline for IFALD in parenteral nutrition-dependent patients, aiming to be the first approved therapy and holding FDA orphan drug and fast track designations. The company distinguishes itself by pursuing late-stage assets with clear regulatory and commercialization paths, backed by leadership with biopharma and finance experience, aiming to obtain regulatory approvals and bring therapies to patients with significant unmet needs.
Explore more opportunities at Protara Therapeutics